MDMA THERAPY

The question of whether psychedelic therapy can restore your vision after venlafaxine (an antidepressant) touches upon multiple topics simultaneously: medication side effects, rare but serious eye problems, stress and so-called functional complaints, and the (still limited) scientific knowledge regarding psychedelics in a therapeutic context. In this article, we outline the key points, emphasizing nuance and safety. We do not make unsubstantiated claims, and we do not promise recovery.

It is important to state upfront: at this moment, there is no sound scientific evidence that a psychedelic session (such as with psilocybin or LSD) can reverse severe or long-term vision loss after venlafaxine. If people experience anything regarding this, it usually involves individual anecdotal accounts. These can be valuable, but they are not proof and say little about predictability or safety.

What is this question essentially about?

The core question is: if your vision deteriorated after venlafaxine, can psychedelic therapy “restore” it? That requires two separate clarifications.

First: what is the suspected cause of the vision problem? This can vary from an ophthalmological problem (for example, eye pressure) to a neurological cause, or a combination of factors. Second: what can psychedelic therapy do in general? Psychedelics can influence perception, emotions, stress responses, and thought patterns. That is different from “repairing” damage to the eye or the optic nerve.

If your symptoms started after medication, it is especially important not to conclude too quickly that it is “stress.” Even if stress plays a role, it must first be carefully ruled out that there is a medical cause requiring attention or treatment.

Venlafaxine and rare but serious eye risks

In rare cases, venlafaxine may be associated with intraocular pressure problems, including acute angle-closure glaucoma. This is an emergency situation in which intraocular pressure can rise rapidly and there is a risk of permanent damage. Symptoms that may be associated with this include acute loss of vision, severe eye pain, redness, halos around lights, and nausea.

Not everyone with visual complaints after venlafaxine has them, and not every change in vision is permanent. However, due to the potential severity, it is advisable that these types of causes be thoroughly assessed by an ophthalmologist or, in the case of more complex complaints, a neuro-ophthalmologist. An assessment by a psychiatrist alone is usually not intended to rule out ophthalmological causes.

This article is not medical advice, but if a thorough ophthalmological and neurological examination has not yet been performed, that is generally the most logical and safest first step. A psychedelic session as an “experiment” without medical exclusion can be a risk, as it may distract attention from causes that actually need to be treated quickly.

Functional vision loss: real, but complex

Sometimes there is vision loss or visual complaints without a suitable organic explanation being found. In the literature, this is often referred to as “functional vision loss.” This does not mean that someone is faking it or that it is “all in their head” in the popular sense. It means that the way the nervous system processes information may be (temporarily) disrupted, without clear structural damage being demonstrated.

It is estimated that functional visual complaints constitute a significant proportion of ophthalmological and neuro-ophthalmological cases. At the same time, diagnosis is difficult: “no explanation found” is not the same as “there is no explanation”. Therefore, a thorough neuro-ophthalmological assessment is important before focusing on functional mechanisms.

If functional factors are indeed plausible, stress, anxiety, hypervigilance (paying close attention to symptoms), avoidance, and tense expectations can play a maintaining role. In such situations, the question is not only “what started it,” but also “what keeps it going.” That is precisely the area where therapy in general can be relevant.

What does science say about psychedelics and vision recovery?

There is interesting research into psychedelics, neuroplasticity, and the way the brain reorganizes networks. In preclinical and partially human research, there are indications that substances such as psilocybin and LSD can influence processes associated with plasticity. It is also known that psychedelics can alter activity and connectivity in the visual cortex, among other areas. This aligns with the well-known effect of visual distortions and hallucinations during a trip.

However, there is an important nuance here: changes in visual processing during intoxication do not automatically mean that damaged or chronically impaired vision improves permanently afterward. Scientifically speaking, the leap from “the brain is temporarily active differently” to “vision recovers structurally” is significant. For vision loss following venlafaxine, there is no strong clinical evidence that psychedelic therapy can restore it.

Therefore, the most honest answer is: if someone promises that psychedelics will restore your vision after venlafaxine, that person is going beyond what is substantiated. That does not mean that no one can ever experience improvement, but it is not predictable, not well-researched, and there is uncertainty regarding mechanisms and safety in this specific situation.

So what can psychedelic therapy actually mean?

If a serious ophthalmological or neurological cause has been thoroughly ruled out, and if stress, anxiety, or a functional mechanism appears to play a major role, then there is a theoretical route through which a psychedelic session could indirectly help. Not by “curing” the eye, but by influencing factors that can worsen or perpetuate symptoms.

Consider, for example:

1) Reduction of anxiety and panic surrounding the complaint, preventing you from getting caught in a vicious cycle of tension and focusing on symptoms.

2) Emotional processing of a major medical experience or medication course. A sudden change in vision can be traumatic, even if doctors find no clear explanation.

3) Breaking rigid thought patterns, such as catastrophizing (“this will only get worse”) or constant checking (“I have to constantly check if I can still see properly”).

4) More acceptance and self-compassion, which can support daily functioning, regardless of whether vision changes objectively.

However, these are possible therapeutic effects on coping, stress regulation, and meaning-making. They are not the same as measurable recovery of visual acuity. In a responsible process, you would also phrase this as follows: the goal is not “restoring vision,” but “learning to deal better with what is” and “investigating whether relaxation and processing create space for change.”.

Safety and harm reduction: what is sensible to bring along?

If someone considers exploring a psychedelic session in a therapeutic context despite the uncertainty, harm reduction is essential. Psychedelics can trigger intense anxiety, disorientation, or a difficult experience, especially if there is already a lot of stress and uncertainty surrounding health.

Practical points often relevant to harm reduction (general, not as individual medical advice):

A) Ensure medical exclusion of urgent causes. In the case of vision complaints, “the ophthalmologist or neuro-ophthalmologist first” is usually a logical priority.

Two) Be honest about expectations. Entering a session with the attitude of “this is supposed to fix my vision” can increase pressure and amplify disappointment. An inquisitive attitude is more realistic.

Three) Set and setting are not details but prerequisites. A safe setting, good preparation, and appropriate guidance can reduce the risk of panic and escalation.

Four) Integration is crucial. If emotional themes surface, it is important that you are able to process them afterwards and translate them into daily life.

It is also important to remain clear regarding the context: MDMA sessions can currently only be discussed and approached within scientific research or in clinical practice via harm reduction. This means that it is not a “regular treatment” with a guaranteed outcome, but rather an approach where safety, preparation, and aftercare are central, within the limits of what is possible and responsible in practice.

What does a personal story reveal, and what doesn't it?

Online, you sometimes read stories from people who notice an improvement in physical or sensory complaints after a psychedelic experience. Such experiences can be genuine and offer hope. At the same time, they are difficult to interpret. Without measurements before and after, without a diagnosis, and without ruling out other factors, you do not know exactly what has changed and why.

In addition, psychedelics can temporarily affect perception. A person may feel they see “more clearly” during or shortly after a session, while it is unclear whether the underlying objective vision has changed. This makes it especially important to be cautious with conclusions.

If you wish to delve deeper into this topic based on the original research question, you can read the source context via this discussion of impaired vision after antidepressants and psychedelics. View that as background information, not as evidence or treatment advice.

When might it be appropriate to consider therapy?

Apart from psychedelics, therapy can be beneficial when visual complaints lead to anxiety, avoidance, depression, or a loss of control. This may involve talk therapy, trauma therapy, or another form of guidance. Psychedelic therapy is sometimes considered when people reach a dead end, but in the case of vision loss following venlafaxine, it is especially important that the approach remains realistic and does not replace medical care.

If, following medical exclusion, you still wish to explore whether a guided session (within a harm-reduction framework) could be beneficial for stress, processing, and quality of life, an exploratory conversation can help discuss expectations, safety, and feasibility. You can register for an exploratory intake via https://mdmatherapie.nl/aanmelden-mdma-sessie/.

Conclusion

There is currently no convincing scientific evidence that psychedelic therapy can restore vision after venlafaxine. Because venlafaxine can be associated with serious eye problems in rare cases, careful medical exclusion by an ophthalmologist (or neuro-)ophthalmologist is an important first step. If organic causes are ruled out and stress or functional mechanisms may be involved, therapy, possibly including a psychedelic session in a harm-reduction context, could theoretically help indirectly through stress reduction and processing. However, this remains uncertain and is no guarantee of vision improvement.